Printed From BioPortfolio.com
[Comment] Ceftazidime-avibactam versus meropenem for the treatment of nosocomial pneumonia
18:36 EST 15 Dec 2017 | The Lancet
Nosocomial pneumonia remains one of the most common, costly, and deadly hospital-acquired infections worldwide.1 Ventilator-associated pneumonia accounts for about half of all hospital-acquired pneumonias and is the second most common nosocomial infection in patients in the intensive-care unit.1,2 Despite extensive work to prevent ventilator-associated pneumonia, an audit by the US Centers for Medicare and Medicaid Services showed no meaningful decrease in the frequency of the infection in US hospitals during the past decade.
Original Article: [Comment] Ceftazidime-avibactam versus meropenem for the treatment of nosocomial pneumonia
